Skip to main content

Alnylam Pharmaceuticals Value Stock - Dividend - Research Selection

Alnylam pharmaceuticals

ISIN: US02043Q1076 , WKN: A0CBCK

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company\'s clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia. Its clinical programs also include ALN-TTRsc02, an investigational RNAi therapeutic targeting TTR, which is in the Phase I clinical trial for the treatment of various forms of ATTR amyloidosis; Lumasiran (ALN-GO1) that is in Phase I/II clinical trial for the treatment of primary hyperoxaluria type 1; and Cemdisiran (ALN-CC5), which is in the Phase II clinical trial for the treatment of complement-mediated diseases. The company has strategic alliances primarily with Sanofi Genzyme; The Medicines Company; Monsanto Company; Takeda Pharmaceutical Company Limited; Ionis Pharmaceuticals, Inc; and Regeneron Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Alnylam Launches Hereditary ATTR Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease

2024-03-14
CAMBRIDGE - Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today announced the launch of the Family Health History Road Trip, its program designed to encourage conversations...

Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease

2024-03-13
CAMBRIDGE, Mass., March 13, 2024--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the launch of the Family Health History Road Trip, its program designed to encourage conversations between family members about their health history so they can discuss with their doctor to better understand their risk for developing an inherited disease like hereditary ATTR (hATTR) amyloidosis. Inspired by the traditional family road trip, the program follows ge

Billionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ Portfolio

2024-03-13
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY

2024-03-11
NEW YORK, March 11, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Alnylam Pharmaceuticals, Inc.  . Such investors are advised to contact Robert...

Is Alnylam's HELIOS-B Delay A Red Flag?

2024-03-10
Alnylam has pushed back the data readout for its HELIOS-B trial from early 2024 to June/July 2024. Read my analysis of ALNY stock.

Pharma Stock Roundup: Novo Nordisk's New Obesity Pill Data, Roche, AstraZeneca's Pipeline Updates

2024-03-09
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Analysts Are Bullish on Top Healthcare Stocks: DarioHealth (DRIO), United Therapeutics (UTHR)

2024-03-07
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Alnylam (ALNY), Roche's Blood Pressure Drug Meets Study Goal

2024-03-06
Data from a mid-stage study shows that Alnylam (ALNY) and Roche-partnered zilebesiran, when added to standard-of-care, lowers blood pressure significantly in adults with mild-to-moderate hypertension.

Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Alnylam Pharma (ALNY) and IO Biotech (IOBT)

2024-03-06
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Buy Rating Affirmed for Alnylam Pharma as Zilebesiran Shows Blockbuster Potential

2024-03-06
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.